Merrill Lynch maintains Actelion sell rating

Actelion Ltd. was maintained by Merrill Lynch analyst Erica Whittaker at a sell rating based on Merrill Lynch's view that the market is overly optimistic about the long-term prospects of Tracleer given emerging competition, and that it will fail to show a significant clinical effect in pulmonary fibrosis. Other pipeline products are in early stages and too risky to include in Merrill Lynch's valuation. Shares of the Allschwil, Switzerland, pharmaceutical company last traded at CHF 99.50.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.